892664-17-4Relevant academic research and scientific papers
Development of an in vivo active, dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostere
Downey, Jason D.,Saleh, Sam A.,Bridges, Thomas M.,Morrison, Ryan D.,Scott Daniels,Lindsley, Craig W.,Breyer, Richard M.
, p. 37 - 41 (2013/02/23)
Recent preclinical studies demonstrate a role for the prostaglandin E 2 (PGE2) subtype 1 (EP1) receptor in mediating, at least in part, the pathophysiology of hypertension and diabetes mellitus. A series of amide and N-acylsulfonamid
Selection and development of the manufacturing route for EP1 antagonist GSK269984B
Whiting, Matthew,Harwood, Kathy,Hossner, Frank,Turner, Peter G.,Wilkinson, Mark C.
, p. 820 - 831 (2011/03/19)
A potential manufacturing route for the EP1 antagonist GSK269984B was developed. Four synthetic approaches were examined, and a successful realisation of each is presented. The rationale supporting selection of the preferred route is discussed.
PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES
-
Page/Page column 40, (2008/06/13)
Compounds of formula (I) or a pharmaceutiically acceptable derivative thereof: wherein X, Y, Z, R2a, R2b, R3a, R3b, R8, R9, and Rx are as defined in the specification, a process
